Trial | NCT01171014  Report issue

Title

Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms
A Three-Arm, Placebo Controlled, Double-Blind, Single Center Study to Evaluate the Impact of Probiotic Strain Bifidobacterium Lactis HN019 on Intestinal Well-Being, Colonic Transit Time and Digestive Discomfort

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    bifidobacterium lactis ...

  • Study Participants

    100
The purpose of this study was to investigate the dose response effect of Bifidobacterium lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms.
Study Started
Jun 30
2009
Primary Completion
Dec 31
2009
Study Completion
Dec 31
2009
Last Update
Jul 28
2010
Estimate

Dietary Supplement Bifidobacterium lactis HN019

Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days

Dietary Supplement Placebo

Placebo, once a day for 14 days

Dietary Supplement Bifidobacterium lactis HN019

Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days

High dose probiotic Experimental

Bifidobacterium lactis HN019, 10 billion cfu/day

Low dose probiotic Experimental

Bifidobacterium lactis HN019, 1 billion cfu/day

Placebo Placebo Comparator

Placebo

Criteria 

Inclusion Criteria:

healthy males and females aged 25 to 65 years
stool type 2-4 on the Bristol Stool Chart
1 to 3 bowel movements per week

Exclusion Criteria:

use of any probiotic product intended to improve gastrointestinal function within the 2 weeks preceding study entry
major chronic and uncontrolled systemic medical conditions
severe gastrointestinal conditions known to prolong CTT
lactose intolerance
chronic diarrhea
gastric bypass surgery or lap band insertion for weight loss
regular laxative use
pregnant or breast-feeding women
No Results Posted